Proprietor of Arkansas Derby Winner Named Horse Right after the Lifetime-Transforming Accuray CyberKnife® Radiation Remedy Technologies Utilized to Handle His Cancer

SUNNYVALE, Calif., April 21, 2022 /PRNewswire/ — When Al Gold, the proprietor of the Arkansas Derby winner Cyberknife, received a diagnosis of prostate most cancers, he was established to come across a prospective heal for his disorder even though minimizing the impact of treatment method on his day-to-day life. Mr. Gold’s exploration led him to a referral for therapy working with the Accuray Integrated (NASDAQ: ARAY) CyberKnife® Method. His serious-globe expertise and good effects compelled him to name a racehorse immediately after the company’s one-of-a-kind robotic technological know-how.

Al Gold’s Cyberknife profitable the Arkansas Derby. Coady Pictures

Like countless other males, Mr. Gold hadn’t experienced any signs prior to learning he experienced prostate cancer. A biopsy verified his ailment and immediately after discovering his options he underwent 5 treatments sessions with the CyberKnife Procedure, a non-invasive cure program, each and every lasting about 18 minutes. Mr. Gold credits his therapy with enabling him to carry on shelling out time with loved ones and taking part in actions he loves – this kind of as looking at his horse, Cyberknife, acquire the Arkansas Derby. This is Mr. Gold’s initial win at a race of this kind of large caliber, a grade 1 results, and he is wanting ahead to the following challenge when his horse races in the Kentucky Derby on May 7.

“When I was first informed I had most cancers, worry overtook all reasonable thought. Will I endure, what kind of procedure will I have, what about my family members? Mastering about the CyberKnife Method gave me hope for my upcoming. CyberKnife was a uncomplicated, discomfort-free of charge cure that enabled me to go on having fun with my daily life. Grateful to the thriving treatment, I named my most promising horse Cyberknife,” stated Al Gold.

Prostates and Sufferers Shift – Motion Matters
A lot of persons will not understand that the prostate moves unpredictably in the course of the study course of therapy – occasionally as much as fifty percent an inch or 12 millimeters because of ordinary client bodily functions these as filling of the bladder, gasoline in the bowel, or even slight affected person motion for the duration of the procedure. This motion can make remedy notably complicated due to the fact of the prostate’s proximity to other sensitive anatomy like the bladder and rectum.

Failing to match the shipping and delivery of radiation remedy with the prostate motion can result in amplified dose shipped to wholesome tissues encompassing the tumor and lowered dose sent to the tumor alone. This can influence the overall procedure success and boost the prospective for facet outcomes that impact a patient’s excellent of life.

The CyberKnife Big difference – Stays on Target Each and every Treatment, Every Client. Automatically
The CyberKnife Process is the only radiation shipping gadget that can detect when the prostate moves and working with artificial intelligence, synchronize the therapy supply beam to the prostate’s new position in actual-time all over the entire procedure session.

The CyberKnife Program characteristics a linear accelerator mounted to a robotic arm that is especially built to provide radiation beams from most likely countless numbers of special angles, targeting only the tumor though reducing radiation dose to healthier tissue. It is this precision, built achievable by the system’s robotic arm and continual tracking and automatic synchronization of the radiation beam, which helps make these types of a variation for clients. In truth, CyberKnife precision is sub-millimeter, indicating its pinpoint precision is much less than the thickness of a coin, even as the prostate moves unpredictably.

“Hearing from folks like Mr. Gold who have been productively treated with a single of the Accuray radiation shipping and delivery systems reinforces why our workers have picked out to do what they do. Our team is focused to establishing ultra-exact technologies like the CyberKnife® Method which has served men about the planet overcome prostate most cancers and resume healthful, complete lives,” stated Suzanne Winter, president at Accuray. “We congratulate Mr. Gold on his Arkansas Derby earn and will be standing up coming to him in spirit as we cheer for his a few-year-outdated colt Cyberknife throughout the Kentucky Derby.”

Continued Ms. Winter season, “The CyberKnife Procedure has nearly two decades of clinical evidence supporting its use which include the Rate-B demo, which confirmed that late grade two or greater bladder toxicities ended up skilled 50% considerably less usually with the Accuray machine as opposed to other radiation treatment devices two several years right after procedure. The higher diploma of accuracy with which the CyberKnife Procedure delivers radiation to prostate tumors can also be utilized to tumors of the mind, breast, kidney, liver, lung, pancreas, backbone, and far more.”

Critical Basic safety Info
For Significant Protection Information and facts be sure to refer to

About Accuray
Accuray is fully commited to growing the effective potential of radiation remedy to increase as many life as probable. We invent distinctive, market place-altering answers that are intended to deliver radiation therapies for even the most intricate cases—while making commonly treatable conditions even easier—to meet up with the total spectrum of patient requirements. We are dedicated to ongoing innovation in radiation remedy for oncology, neuro-radiosurgery, and further than, as we husband or wife with clinicians and administrators, empowering them to assist sufferers get again to their lives, more quickly. Accuray is headquartered in Sunnyvale, California, with amenities around the globe. To find out more, pay a visit to or stick to us on Facebook, LinkedIn, Twitter, and YouTube.

Secure Harbor Assertion
Statements designed in this press launch that are not statements of historic fact are forward-hunting statements and are subject to the “safe and sound harbor” provisions of the Private Securities Litigation Reform Act of 1995. Ahead-wanting statements in this push release relate, but are not restricted, to medical programs, clinical benefits, patient activities and affected person results. These ahead-on the lookout statements contain pitfalls and uncertainties. If any of these threats or uncertainties materialize, or if any of the company’s assumptions show incorrect, genuine benefits could differ materially from the success expressed or implied by these ahead-hunting statements. These risks and uncertainties incorporate, but are not minimal to, pitfalls discovered below the heading “Risk Elements” in the company’s quarterly report on Form 10-Q, filed with the Securities and Exchange Fee (the “SEC”) on January 26, 2022, and as current periodically with the company’s other filings with the SEC.

Forward-wanting statements converse only as of the day the statements are manufactured and are based on details available to the firm at the time individuals statements are made and/or management’s excellent religion perception as of that time with respect to upcoming occasions. The enterprise assumes no obligation to update ahead-looking statements to replicate actual overall performance or results, alterations in assumptions or modifications in other elements influencing forward-hunting information, besides to the extent necessary by relevant securities rules. Accordingly, traders need to not set undue reliance on any forward-seeking statements.

Media Contact:
Beth Kaplan
Community Relations Director, Accuray
+1 (408) 789-4426
[email protected]

Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated)

Accuray Integrated (PRNewsFoto/Accuray Integrated) (PRNewsFoto/Accuray Integrated)



Watch primary material to obtain multimedia: cancers-301529800.html

Source Accuray Included